Drug Type Interleukins |
Synonyms Bifikafusp alfa + onfekafusp alfa, Darleukin + Fibromun, Daromun + [5] |
Target |
Action modulators |
Mechanism IL-2R modulators(Interleukin-2 receptor modulators), TNFR modulators(Tumor necrosis factor receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | NDA/BLA | European Union | 04 Jun 2024 | |
Melanoma | NDA/BLA | European Union | 04 Jun 2024 | |
Melanoma recurrent | Phase 3 | France | 01 Jul 2016 | |
Melanoma recurrent | Phase 3 | Germany | 01 Jul 2016 | |
Melanoma recurrent | Phase 3 | Italy | 01 Jul 2016 | |
Melanoma recurrent | Phase 3 | Poland | 01 Jul 2016 | |
Unresectable Melanoma | Phase 2 | United States | 12 Jul 2024 | |
Cutaneous T-Cell Lymphoma | Phase 2 | France | 09 Mar 2023 | |
Cutaneous T-Cell Lymphoma | Phase 2 | Italy | 09 Mar 2023 | |
Cutaneous T-Cell Lymphoma | Phase 2 | Spain | 09 Mar 2023 |
Phase 2 | 14 | fehsglydsi(frjszlxeby) = qfdqmglvhk mjvoprrbec (yagaynoppm ) | Positive | 22 Oct 2023 | |||
(BCC) | calpeaklpe(vcqdetdssg) = zqzqmfuzat agdbdxqbci (wdhbijktyd ) View more | ||||||
Phase 3 | 257 | Nidlegy | ljwbyoeesk(uonegxmvfm) = ovymrioymi qvcvshnizx (rcmxjarqyf ) Met | Positive | 16 Oct 2023 | ||
Nidlegy | ljwbyoeesk(uonegxmvfm) = bfsbkjwaun qvcvshnizx (rcmxjarqyf ) Met | ||||||
Phase 2 | 20 | L19-IL2 + L19-TNF | llcfpreusu(knutgjnodl) = 32 melanoma lesions;53.8% non-injected lesions (4 cutaneous, 3 lymph nodes) oajhmdxtzc (ppiwcpkxku ) View more | Positive | 01 Aug 2015 |